Biogen/Eisai Will Explore Volume-Based Discounts For Aduhelm In Medicare

24 Jun 2021

Deal with Veterans Administration also expected; companies say they will work with payers to ‘address’ pricing if patient population and uptake for their Alzheimer's drug are greater than expected.

Patient From Early Stage Aducanumab Trial At Left • Source: Alamy

Biogen, Inc. and partner Eisai Co., Ltd. are open to providing the Medicare program volume-based discounts on their recently approved drug for Alzheimer’s disease in recognition of the financial burden the $56,000 per year treatment could impose on the program.

The companies set the launch price for the drug based on their “belief in the impact of treatment as well...